. Author manuscript; available in PMC: 2013 Oct 1.

Published in final edited form as: Curr Alzheimer Res. 2012 Oct;9(8):990–997. doi: 10.2174/156720512803251075

Table 2.

Effects of Atorvastatin vs. Placebo on Changes in Outcome Measures Compared to Baselin

Characteristics	Atorvastatin Group	Placebo Group	p Value (difference between groups)

	N=8	N=8
Serum Cholesterol Levels

Serum total cholesterol, mean change (SD), mg/dL [mmol/L]	−59.1 (28.3) [−1.5 (0.7)]	−1.8 (13.6) [0.0 (0.4)]	0.002
Serum triglycerides, mean change (SD), mg/dL [mmol/L]	−49.1 (36.7) [−0.6 (0.4)]	−12.9 (19.4) [−0.1 (0.2)]	0.024
Serum HDL-C, mean change (SD), mg/dL [mmol/L]	3.9 (9.3) [0.1 (0.2)]	−1.0 (7.7) [0.0 (0.2)]	0.226
Serum LDL-C, mean change (SD), mg/dL [mmol/L]	−53.8 (21.5) [−1.4 (0.6)]	2.0 (11.6) [0.0 (0.3)]	0.001

Peripheral Vasoreactivity Measures

Flow-mediated vasodilation (60 sec), mean change (SD), %	−0.4 (2.1)	0.3 (2.3)	0.462

Global MRI Cerebral Perfusion Measures

Global CBF, mean change (SD), ml/100g/min (n=13)	−5.0 (18.8)	−14.0 (16.7)	0.199

HDL-C=high density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; CBF=cerebral blood flow; ASL-MRI=arterial spin-labeling magnetic resonance imaging.